Phathom Pharmaceuticals PHAT 深 滬
已收盤 11-06 16:00:00 美东时间
5.25
+0.170
+3.35%
華盛通- 最 高5.305
- 今 開5.26
- 成交量 177.08万股
- 最 低 5.04
- 昨 收 5.08
- 總市值 42.68万
- 52周最高 18.31
- 市盈率 靜 --
- 換手率 2178.39%
- 52周最低 5.015
- 委 比 57.38%
- 總股本 8.13万
- 歷史最高 64.54
- 量 比 0.92
- 振 幅 5.22%
- 歷史最低 2.21
- 每 手 1
- 風險率 2.81%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Phathom Pharmaceuticals to Participate in November Investor Conferences
Phathom Pharmaceuticals announced that its management team will participate in three upcoming investor conferences: the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston on November 10, 2026; the Stifel 2026 Healthcare Conference in New York on November 11, 2026; and the Jefferies Global Healthcare Conference in London on November 18, 2026. The company’s leadership will engage in fireside chats and one-on-one meetings at each event...
11-04 13:00
Phathom Pharmaceuticals收涨3.05%，成交额1608.92万美元
11月3日，Phathom Pharmaceuticals（PHAT）收涨3.05%，报5.92美元，成交额1608.92万美元，市值4.79亿美元。 行情数据...
11-03 07:06
Phathom Pharmaceuticals (PHAT) Q3 2026 Earnings Call: Revenue Rises 71%, Guidance Reaffirmed
Phathom Pharmaceuticals’ Q3 2026 earnings call covered $84.7 million in revenue, positive operating profit, VOQUEZNA growth and reaffirmed guidance.
10-29 20:07
Phathom Pharmaceuticals收跌18.12%，成交额2752.92万美元
10月24日，Phathom Pharmaceuticals（PHAT）收跌18.12%，报5.74美元，成交额2752.92万美元，市值4.64亿美元。 行情...
10-24 06:11
Phathom Defends VOQUEZNA Exclusivity Amid FDA Lawsuit
The latest announcement is out from Phathom Pharmaceuticals ( ($PHAT) ). On Oct...
10-24 05:30
Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
Phathom Pharmaceuticals announced that BDR Pharmaceuticals has filed a lawsuit against the FDA, challenging its refusal to accept an ANDA referencing Phathom's NDA for VOQUEZNA®. BDR alleges the FDA improperly extended Phathom's NCE exclusivity under the GAIN Act. Phathom believes the FDA correctly granted 10 years of exclusivity for VOQUEZNA tablets through May 2032 and plans to defend its exclusivity. VOQUEZNA is used to treat GERD and H. pylor...
10-23 08:00
Phathom Pharmaceuticals收跌7.73%，成交额885.24万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:05
Phathom Pharmaceuticals To Present New Cost-Effectiveness Data For VOQUEZNA At The American College Of Gastroenterology Meeting, October 9-14;
New analysis projects VOQUEZNA® (vonoprazan) to provide meaningful economic value and be cost-effective vs. proton pump inhibitors (PPIs) for adults with Erosive GERD, with potential cost savings at net price based on clinical healing and maintenance-of-healing data and fewer anticipated downstream ...
10-12 20:03
Phathom’s Vonoprazan Trial Targets Episodic Heartburn Upside for PHAT Investors
Phathom Pharmaceuticals, Inc. ($PHAT) announced an update on their ongoing clin...
10-08 00:30
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
